HealthQuill Novartis AG
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

Read More
Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight management and metabolism, and invest $50 billion in the country over five years.
Drugs Health Pharma

AstraZeneca to invest $50 billion in US, to build new drug facility

HQ Team July 22, 2025: Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight.

Read More
Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved in Switzerland, and eight African nations are set to follow.
Drugs Health Pharma

Novartis malaria drug for infants gets Swiss nod, 8 African nations in line

HQ Team July 8, 2025: Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved.

Read More
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Drugs Health Pharma

Novartis to pay Monte Rosa $150m upfront for MGD drug candidates

Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.

Read More
Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of patients with a rare type of kidney disease.
Drugs Health Pharma

Novartis’s drug to treat rare kidney disease gets USFDA approval 

Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of.

Read More
Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion.
Drugs Health Pharma

Novartis AG to buy Mariana Oncology for $1 billion to build RLT assets

HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..

Read More
Voyager Therapeutics, Inc., will receive an upfront payment of $100 million from Switzerland-based Novartis AG to develop gene therapies for two genetic disorders.
Drugs Health Pharma

Novartis to pay $100m upfront to Voyager for gene therapies

HQ Team January 3, 2023: Voyager Therapeutics, Inc., will receive an upfront payment of $100 million from Switzerland-based Novartis AG to develop gene.

Read More
The US drug regulator gave its nod for Sandoz Inc., an arm of Sweden-based Novartis and which is set to be Europe’s largest generic drugmaker, for a biosimilar, Tyruko, to treat adults with multiple sclerosis.
Drugs Health Pharma

USFDA green lights Sandoz’s biosimilar Tyruko to treat multiple sclerosis  

HQ Team August 25, 2023: The US drug regulator gave its nod for Sandoz Inc., an arm of Sweden-based Novartis and which is.

Read More
Drugs Medical Pharma

Novartis sells eye business to Bausch+Lomb for $2.5 billion

HQ Team July 3, 2023: Swiss drugmaker Novartis is divesting its ophthalmology assets including Xiidra, an anti-inflammatory eye drop to Bausch + Lomb,.

Read More